Literature DB >> 12143296

Best practice treatment algorithm for primary open-angle glaucoma: implications for U.S. ophthalmology practice.

Janet Serle1, Louis Cantor, Ron Gross, Jay Katz, Thomas Mundorf, Robert Noecker, Todd Severin, Steve Simmons, John Walt, Julian Casciano, Stacy Evans, John Doyle.   

Abstract

The objective of this study was to develop a "best-practice" treatment algorithm for the management of primary open-angle glaucoma in patients receiving initial medical therapy, to serve as a consideration for future ophthalmology practice. For comparison, a baseline, "common-practice" treatment algorithm was also created that reflects current ophthalmology practice patterns. Survey instruments were developed based on a comprehensive review of relevant literature, along with input from a general ophthalmologist. A panel of eight ophthalmologists subspecialized in glaucoma management was surveyed. Consensus was achieved using a modified Delphi technique. A comparison of common- and best-practice treatment algorithms suggests that in contrast with expert opinion, nonselective beta blockers are currently used more often, and alpha-2 agonists less often, as first-line therapy for the treatment of primary open-angle glaucoma.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12143296

Source DB:  PubMed          Journal:  Manag Care Interface        ISSN: 1096-5645


  4 in total

Review 1.  Prostaglandin analogues for the treatment of glaucoma and ocular hypertension: a systematic review of economic evidence.

Authors:  Michelle Orme; Annabel Boler
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 2.  The economic burden of glaucoma and ocular hypertension: implications for patient management: a review.

Authors:  Jean-François Rouland; Gilles Berdeaux; Antoine Lafuma
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

3.  Cost considerations in the medical management of glaucoma in the US: estimated yearly costs and cost effectiveness of bimatoprost compared with other medications.

Authors:  Lawrence D Goldberg; John Walt
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

4.  Cost of glaucoma treatment in a developing country over a 5-year period.

Authors:  Gabriel Lazcano-Gomez; María de Los Angeles Ramos-Cadena; Margarita Torres-Tamayo; Alejandra Hernandez de Oteyza; Mauricio Turati-Acosta; Jesús Jimenez-Román
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.